Svetlana Trestman

Tel Aviv University — Israel

Medicine · Health Sciences

12h-index633citations59works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(43), Protein Degradation and Inhibitors(14), Peptidase Inhibition and Analysis(10), Chronic Lymphocytic Leukemia Research(8), Metabolism, Diabetes, and Cancer(6)

Publications59 total

Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable Outcomes
Cancers·2026Open Access
Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network
Blood·2025Open Access
Deep-Learning-Based Prediction of t(11;14) in Multiple Myeloma H&E-Stained Samples
Cancers·2025· 1 citedOpen Access
Acquired FX Deficiency in Multiple Myeloma Without Concomitant Amyloidosis- A Rare Case Report
Acta Haematologica·2025Open Access
Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease is Associated with Favorable Outcomes
SSRN Electronic Journal·2025Open Access
Treatment Modalities and Outcomes of Multiple Myeloma Patients with Spinal Cord Compression: A Single Center Experience
Blood·2024
The Outcome of Octogenarian Patients with Multiple Myeloma Treated Outside Clinical Studies, Focusing on Tolerability and Efficacy of Treatment
Cancers·2024· 1 citedOpen Access
Smoldering Multiple Myeloma Progressing to Active Multiple Myeloma Vs De-Novo Active Multiple Myeloma - a Comparison of Disease Characteristics, Organ Involvement and Outcomes in a Real-Life Multicenter Retrospective Cohort Study
Blood·2023· 3 citedOpen Access
Treatment with low‐dose, single‐agent belantamab mafodotin is safe and provides long‐term responses in heavily pretreated multiple myeloma patients
European Journal Of Haematology·2023· 1 citedOpen Access
POSTER: MM-362 Multiple Myeloma Oligosecretory Relapse: A Cross-Sectional Historical Cohort Study
Clinical Lymphoma Myeloma & Leukemia·2023
MM-362 Multiple Myeloma Oligosecretory Relapse: A Cross-Sectional Historical Cohort Study
Clinical Lymphoma Myeloma & Leukemia·2023
P966: SMOLDERING MULTIPLE MYELOMA (MM) PROGRESSING TO ACTIVE MM DURING FOLLOW-UP: REDUCED BONE DISEASE AND IMPROVED PROGRESSION-FREE AND OVERALL SURVIVAL COMPARED TO DE-NOVO NEWLY DIAGNOSED MM
HemaSphere·2023· 1 citedOpen Access
P942: MULTIPLE MYELOMA OLIGOSECRETORY RELAPSE- A CROSS SECTIONAL HISTORICAL COHORT STUDY
HemaSphere·2023Open Access
Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
British Journal of Haematology·2022· 40 citedOpen Access
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group
Leukemia & lymphoma/Leukemia and lymphoma·2022· 4 cited
P-114: Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multi-center retrospective study
Clinical Lymphoma Myeloma & Leukemia·2022
COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge
Cancer Cell·2022· 15 citedOpen Access
Multiple Myeloma Oligosecretory Relapse, a Non-Negligible Phenomenon. Frequency, Clinical Characteristics and Outcomes in a Single Center
Blood·2021· 3 cited
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma
British Journal of Haematology·2021· 73 citedOpen Access
Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study
Therapeutic Advances in Hematology·2021· 19 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Yaël C. Cohen(37), Irit Avivi(35), Tamir Shragai(16), Moshe E. Gatt(12), Noam Benyamini(11), Efrat Luttwak(11), Hila Magen(11), Noa Lavi(11), Tamar Tadmor(11), Iuliana Vaxman(9), Natan Melamed(9), Yair Herishanu(8), Moshe Mittelman(7), Chezi Ganzel(7), Tomer Ziv‐Baran(7), Elizabeth Naparstek(7), Meletios Α. Dimopoulos(6), Netanel A. Horowitz(6), Chava Perry(6), Erel Joffe(6)